

[illegible][illegible][illegible]

Emily Le

January 15, 2005

908979

INFORMATION DISCLOSURE  
CITATION

ATTY. DOCKET NO.

SERIAL NO.

2370-11

08/260,536

APPLICANT


Robert M. LORENCE et al

FILING DATE

TC/A.U.

June 16, 1994

1648



(Use separate sheets if necessary)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

eh	Povlsen, C.O.; "Status of Chemotherapy, Radiotherapy, Endocrine Therapy, and Immunotherapy Studies of Human Cancer in the Nude Mouse"; <i>The Nude Mouse in Experimental and Clinical Research</i> ; Academic Press, New York, San Francisco, London; pp. 437-457 (1978).
	Thorne, S.H., et al; "Future Directions for the Field of Oncolytic Virotherapy: A Perspective on the Use of Vaccinia Virus"; <i>Expert Opin. Biol. Ther.</i> ; Vol. 4, No. 8; pp 1307-1321 (2004).
	Poster (ASCO Meeting); "Slow Intravenous Infusion of PV701, An Oncolytic Virus: Final Results of a Phase Study"; <i>2004 Am. Soc. Clin. Oncology (ASCO) Mtg.</i>
	Schirrmacher, V., et al; "Virus Potentiation of Tumor Vaccine T-Cell Stimulatory Capacity Requires Cell Surface Binding but not Infection"; <i>Clinical Cancer Research</i> ; Vol. 3; pp. 1135-1148 (1997).
	Zorn, U., et al; "Induction of Cytokines and Cytotoxicity Against Tumor Cells by Newcastle Disease Virus"; <i>Cancer Biotherapy</i> ; Vol. 9, No. 3; pp. 225-235 (1994).
	Zorn, U., et al; "Active Specific Immunotherapy of Renal Cell Carcinoma: Cellular and Humoral Immune Responses"; <i>Cancer Biotherapy &amp; Radiopharmaceuticals</i> ; Vol. 12, No. 3; pp. 157-165 (1997).
	Plager, C., et al; "Adjuvant Immunotherapy with Newcastle Disease Virus Oncolysate of M.D. Anderson (MDAH) Stage III-B Malignant Melanoma"; Head and Neck, Sarcoma, Melanoma, and Other Solid Tumors; <i>Proceedings of ASCO</i> ; Vol. 4; C-584 p. 150 (1985).
	Plager, C., et al; "Adjuvant Immunotherapy with Newcastle Disease Virus Oncolysate of M.D. Anderson (MDAH) Stage III-B Malignant Melanoma"; Head and Neck, Sarcoma, Melanoma, and Other Solid Tumors; <i>Proceedings of ASCO</i> ; Vol. 5; 534 p. 137 (1986).
	Krishnamurthy, S., et al; "Newcastle Disease Virus as an Oncolytic Agent: Mechanism of Viral Infection, Growth and Oncolysis"; <i>American Society for Virology 21<sup>st</sup> Annual Meeting, University of Kentucky, Lexington, KY, July 20-24, 2002, Scientific Program and Abstracts</i> ; p. 90.
	Batliwalla, F.M., et al; "A 15-Year Follow-up of AJCC Stage III Malignant Melanoma Patients Treated Postsurgically with Newcastle Disease Virus (NDV) Oncolysate and Determination of Alternations in the CD8 T Cell Repertoire"; <i>Molecular Medicine</i> ; Vol. 4; pp. 783-794 (1998).
	Bonaccorsi, P., et al; "Management of High-risk Melanoma"; <i>Medical Dermatology</i> ; Vol. 19, No. 4; pp 727-735 (2001).

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.